Rapamycin Prolongs Cardiac Allograft Survival in a Mouse Model by Inducing Myeloid-Derived Suppressor Cells

American Journal of Transplantation

Volumn 15, Issue 9, 2015, Pages 2364-2377

  Nakamura, T ^a,b   Nakao, T ^a,b   Yoshimura, N ^a   Ashihara, E ^b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Animal models: murine; basic (laboratory) research science; cellular biology; heart (allograft) function dysfunction; heart transplantation cardiology; immune regulation; immunosuppressant; immunosuppression immune modulation; mechanistic target of rapamycin:sirolimus; translational research science

Indexed keywords

ARGINASE; CYCLOSPORIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; RAPAMYCIN; TACROLIMUS; TRAMETINIB; TRANSCRIPTION FACTOR FOXP3; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL MIGRATION; CONTROLLED STUDY; GRAFT SURVIVAL; HEART GRAFT; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; ALLOGRAFT; ANIMAL; C3H MOUSE; C57BL MOUSE; CYTOLOGY; DRUG EFFECTS; FLOW CYTOMETRY; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM;

ALLOGRAFTS; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MYELOID CELLS; NITRIC OXIDE SYNTHASE TYPE II; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84939574415     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13276     Document Type: Article

References (48)

1. Dai Z, Zhang S, Xie Q, et al., Natural CD8+ CD122+ T cells are more potent in suppression of allograft rejection than CD4+ CD25+ regulatory T cells. Am J Transplant 2014; 1: 39-48.
2. Grazia TJ, Plenter RJ, Weber SM, et al., Acute cardiac allograft rejection by directly cytotoxic CD4 T cells: Parallel requirements for Fas and perforin. Transplantation 2010; 1: 33-39.
3. Garcia AJ, Ruscetti M, Arenzana TL, et al., Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. Mol Cell Biol 2014; 11: 2017-2028.
4. Fujii W, Ashihara E, Hirai H, et al., Myeloid-derived suppressor cells play crucial roles in the regulation of mouse collagen-induced arthritis. J Immunol 2013; 3: 1073-1081.
5. Hongo D, Tang X, Baker J, Engleman EG, Strober S., R equirement for interactions of natural killer T cells and myeloid-derived suppressor cells for transplantation tolerance. Am J Transplant 2014; 11: 2467-2477.
6. Dugast AS, Haudebourg T, Coulon F, et al., Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol 2008; 12: 7898-7906.
7. Garcia MR, Ledgerwood L, Yang Y, et al., Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice. J Clin Invest 2010; 7: 2486-2496.
8. Turnquist HR, Zhao Z, Rosborough BR, et al., IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol 2011; 9: 4598-4610.
9. Waight JD, Netherby C, Hensen ML, et al., Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest 2013; 10: 4464-4478.
10. Vasquez-Dunddel D, Pan F, Zeng Q, et al., STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest 2013; 4: 1580-1589.
11. Greifenberg V, Ribechini E, Rossner S, Lutz MB., Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J Immunol 2009; 10: 2865-2876.
12. Zhang Y, Bi Y, Yang H, et al., mTOR limits the recruitment of CD11b+ Gr1+ Ly6Chigh myeloid-derived suppressor cells in protecting against murine immunological hepatic injury. J Leukoc Biol 2014; 6: 961-970.
13. Makki K, Taront S, Molendi-Coste O, et al., Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice. PLoS ONE 2014; 4: e92684.
14. Engelman JA., Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer 2009; 8: 550-562.
15. Inoki K, Zhu T, Guan KL., TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 5: 577-590.
16. Arsham AM, Howell JJ, Simon MC., A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 2003; 32: 29655-29660.
17. Faber AC, Li D, Song Y, et al., Differential induction of apoptosis in HER2, EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci USA 2009; 46: 19503-19508.
18. Carracedo A, Ma L, Teruya-Feldstein J, et al., Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 9: 3065-3074.
19. Wang X, Hawk N, Yue P, et al., Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther 2008; 12: 1952-1958.
20. Valentino JD, Li J, Zaytseva YY, et al., Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors. Clin Cancer Res 2014; 5: 1212-1222.
21. Watson AL, Anderson LK, Greeley AD, et al., Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. Oncotarget 2014; 6: 1502-1514.
22. Couper KN, Lanthier PA, Perona-Wright G, et al., Anti-CD25 antibody-mediated depletion of effector T cell populations enhances susceptibility of mice to acute but not chronic Toxoplasma gondii infection. J Immunol 2009; 7: 3985-3994.
23. Raber PL, Thevenot P, Sierra R, et al., Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways. Int J Cancer 2014; 12: 2853-2864.
24. Youn JI, Collazo M, Shalova IN, Biswas SK, Gabrilovich DI., Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol 2012; 1: 167-181.
25. Delgoffe GM, Kole TP, Zheng Y, et al., The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009; 6: 832-844.
26. Luan Y, Mosheir E, Menon MC, et al., Monocytic myeloid-derived suppressor cells accumulate in renal transplant patients and mediate CD4 Foxp3 Treg expansion. Am J Transplant 2013; 12: 3123-3131.
27. McCubrey JA, Steelman LS, Abrams SL, et al., Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008; 4: 708-722.
28. Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Steelman LS, McCubrey JA., Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. Oncotarget 2011; 8: 610-626.
29. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I., High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004; 17: 6337-6343.
30. Menetrier-Caux C, Montmain G, Dieu MC, et al., Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: Role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998; 12: 4778-4791.
31. Sawanobori Y, Ueha S, Kurachi M, et al., Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008; 12: 5457-5466.
32. Arakawa Y, Qin J, Chou HS, et al., Cotransplantation with myeloid-derived suppressor cells protects cell transplants: A crucial role of inducible nitric oxide synthase. Transplantation 2014; 7: 740-747.
33. Liao J, Wang X, Bi Y, et al., Dexamethasone potentiates myeloid-derived suppressor cell function in prolonging allograft survival through nitric oxide. J Leukoc Biol 2014; 5: 675-684.
34. Hestdal K, Ruscetti FW, Ihle JN, et al., Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol 1991; 1: 22-28.
35. Pautz A, Art J, Hahn S, Nowag S, Voss C, Kleinert H., R egulation of the expression of inducible nitric oxide synthase. Nitric Oxide 2010; 2: 75-93.
36. Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR., Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 1992; 6381: 70-73.
37. Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW., Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 11: 7018-7031.
38. Horibe EK, Sacks J, Unadkat J, et al., Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion. Transpl Immunol 2008; 4: 307-318.
39. Taner T, Hackstein H, Wang Z, Morelli AE, Thomson AW., Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant 2005; 2: 228-236.
40. Chen HW, Chen HY, Wang LT, et al., Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene chemokines. J Immunol 2013; 10: 5065-5077.
41. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR., Evolution of causes and risk factors for mortality post-liver transplant: Results of the NIDDK long-term follow-up study. Am J Transplant 2010; 6: 1420-1427.
42. Eisen HJ, Kobashigawa J, Starling RC, et al., Everolimus versus mycophenolate mofetil in heart transplantation: A randomized, multicenter trial. Am J Transplant 2013; 5: 1203-1216.
43. Opelz G, Dohler B., A ssociation between steroid dosage and death with a functioning graft after kidney transplantation. Am J Transplant 2013; 8: 2096-2105.
44. Collett D, Mumford L, Banner NR, Neuberger J, Watson C., C omparison of the incidence of malignancy in recipients of different types of organ: A UK Registry audit. Am J Transplant 2010; 8: 1889-1896.
45. Rosborough BR, Castellaneta A, Natarajan S, Thomson AW, Turnquist HR., Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo. J Leukoc Biol 2012; 5: 701-709.
46. Dolcetti L, Peranzoni E, Ugel S, et al., Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 2010; 1: 22-35.
47. Bromberg J., Stat proteins and oncogenesis. J Clin Invest 2002; 9: 1139-1142.
48. Yuan H, Cai P, Li Q, et al., Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation. Biomed Pharmacother 2014; 6: 751-756.